507 related articles for article (PubMed ID: 19803538)
1. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
2. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
McCullagh L; Walsh C; Barry M
Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
[TBL] [Abstract][Full Text] [Related]
8. New anticoagulants as thromboprophylaxis after total hip or knee replacement.
Hamidi V; Ringerike T; Hagen G; Reikvam Å; Klemp M
Int J Technol Assess Health Care; 2013 Jul; 29(3):234-43. PubMed ID: 23768996
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
Kotirum S; Chongmelaxme B; Chaiyakunapruk N
J Thromb Thrombolysis; 2017 Feb; 43(2):252-262. PubMed ID: 27704332
[TBL] [Abstract][Full Text] [Related]
10. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Zindel S; Stock S; Müller D; Stollenwerk B
BMC Health Serv Res; 2012 Jul; 12():192. PubMed ID: 22776616
[TBL] [Abstract][Full Text] [Related]
11. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Burness CB; McKeage K
Drugs; 2012 May; 72(7):963-86. PubMed ID: 22564134
[TBL] [Abstract][Full Text] [Related]
16. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Plumb JM; Clemens A; Monz BU
Pharmacoeconomics; 2010; 28(9):781-2; author reply 782-4, 784-5. PubMed ID: 20824908
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
McDonald H; Diamantopoulos A; Wells P; Lees M; Folkerts K; Forster F; Ananthapavan J
J Med Econ; 2012; 15(5):817-28. PubMed ID: 22494267
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
Postma MJ; Kappelhoff BS; van Hulst M; Brouwers JR
J Med Econ; 2012; 15(5):878-86. PubMed ID: 22563715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]